


WHO recommendations for prevention and treatment of maternal peripartum infections



WHO recommendations
for prevention and treatment of
maternal peripartum infections

WHO Library Cataloguing-in-Publication Data

WHO recommendations for prevention and treatment of maternal peripartum infections.

Includes web supplement titled "WHO recommendations for prevention and treatment of maternal peripartum infections: evidence base.

1.Peripartum Period. 2.Pregnancy Complications, Infectious – prevention and control. 3.Puerperal Infections – prevention and control. 4.Puerperal Infections – drug therapy. 5.Guideline. I.World Health Organization.

ISBN 978 92 4 154936 3

(NLM classification: WQ 256)

© World Health Organization 2015

All rights reserved. Publications of the World Health Organization are available on the WHO website (www.who.int) or can be purchased from WHO Press, World Health Organization, 20 Avenue Appia, 1211 Geneva 27, Switzerland (tel.: +41 22 791 3264; fax: +41 22 791 4857; e-mail: bookorders@who.int).

Requests for permission to reproduce or translate WHO publications – whether for sale or for non-commercial distribution – should be addressed to WHO Press through the WHO website (www.who.int/about/licensing/copyright_form/en/index.html).

The designations employed and the presentation of the material in this publication do not imply the expression of any opinion whatsoever on the part of the World Health Organization concerning the legal status of any country, territory, city or area or of its authorities, or concerning the delimitation of its frontiers or boundaries. Dotted and dashed lines on maps represent approximate border lines for which there may not yet be full agreement.

The mention of specific companies or of certain manufacturers' products does not imply that they are endorsed or recommended by the World Health Organization in preference to others of a similar nature that are not mentioned. Errors and omissions excepted, the names of proprietary products are distinguished by initial capital letters.

All reasonable precautions have been taken by the World Health Organization to verify the information contained in this publication. However, the published material is being distributed without warranty of any kind, either expressed or implied. The responsibility for the interpretation and use of the material lies with the reader. In no event shall the World Health Organization be liable for damages arising from its use.

Contents

Acknowledgements	v
Acronyms and abbreviations	vi
Executive summary	1
Introduction	1
Target audience	1
Guideline development methods	1
Recommendations	2
1. Background	4
Definitions and terms	4
Rationale and objectives	5
Target audience	5
Scope of the guideline	5
2. Methods	6
Contributors to the guideline	6
Identification of priority questions and critical outcomes	7
Identification and retrieval of evidence	7
Quality assessment and grading of the evidence	8
Formulation of recommendations	9
Declaration of interests by external contributors	9
Decision-making during the technical consultation	10
Document preparation and peer review	10
3. Results	11
Guiding principles	11
Evidence and recommendations	12
4. Research implications	49
5. Dissemination and implementation of the guideline	49
Guideline dissemination and evaluation	49
Guideline implementation	50
6. Applicability issues	50
Anticipated impact on the organization of care and resources	50
Monitoring and evaluating the guideline implementation	51
7. Updating the guideline	51
8. References	52
Annex 1. External experts and WHO staff involved in the preparation of the guideline	55
Annex 2. Critical and important outcomes for decision-making	59
Annex 3: Summary and management of declared interests from GDG members	64
Annex 4. Summary of the considerations related to the strength of the recommendations (balance worksheets)	66

The standardized criteria used in grading the evidence and GRADE tables are not included in this document although table numbers (prefixed with EB) are included for ease of reference. The tables have been published in a separate document – *WHO recommendations for prevention and treatment of maternal peripartum infections: evidence base* – which can be accessed online at www.who.int/reproductivehealth/publications/maternal_perinatal_health/peripartum-infections-guidelines.

Acknowledgements

The Department of Reproductive Health and Research of the World Health Organization (WHO) gratefully acknowledges the contributions that many individuals and organizations made to the development of this guideline. Work on this guideline was initiated by A. Metin Gülmezoglu and Olufemi Oladapo, of the WHO Department of Reproductive Health and Research, and Matthews Mathai, of the WHO Department of Maternal, Newborn, Child and Adolescent Health. Olufemi Oladapo coordinated the development of the guideline and drafted this document with Mercedes Bonet, also of the WHO Department of Reproductive Health and Research.

WHO extends sincere thanks to Beverly Chambers, Maria Laura Costa, Malik Goonewardene, Julia Hussein, Chowa Kasengele, Pisake Lumbiganon, Ashraf Nabhan, Ruta Nadisauskiene, Alfred Osoti, Xu Qian, Haroon Saloojee, Jeffrey Smith, Subha Sri Balakrishnan, and Adewale Sule-Odu, who served as members of the Guideline Development Group (GDG), and to James Neilson, for chairing the technical consultation.

The technical staff of the Department of Health Policy, National Center for Child Health and Development, Tokyo, Japan, led by Rintaro Mori and Erika Ota, updated and reviewed the scientific evidence from systematic reviews, prepared the GRADE tables and drafted the narrative summaries of evidence used in this guideline. Sonja Henderson, of the Cochrane Pregnancy and Childbirth Group, University of Liverpool, United Kingdom, coordinated the updating of relevant Cochrane reviews and review of the scientific evidence. Olufemi Oladapo and Mercedes Bonet revised the narrative summaries and double-checked the corresponding GRADE tables. A. Metin Gülmezoglu and Matthews Mathai commented on the draft document before it was reviewed by participants at the WHO technical consultation on interventions to prevent and treat maternal peripartum infections. Ayse Akin, Justus Hofmeyr, Dame Tina Lavender, Suneeta Mittal, Jegannathan Ravichandran and Alan Tita were members of the External Review Group who peer-reviewed the final guideline document.

Special thanks are due to the authors of existing Cochrane systematic reviews used in this guideline for their assistance and collaboration in preparing or updating the reviews. WHO is also grateful to the Cochrane Pregnancy and Childbirth Group, especially the staff at their Liverpool office in the United Kingdom, for their support in updating the Cochrane reviews. We appreciate the feedback provided by a large number of international stakeholders during the scoping exercise that took place as part of the guideline development process.

We acknowledge the various organizations that were represented as observers at the final technical consultation, including Sabaratnam Arulkumaran (International Federation of Gynaecology and Obstetrics); Serena Debonnet and Mary Higgins (International Confederation of Midwives); Luc de Bernis (United Nations Population Fund); Mary Ellen Stanton and Deborah Armbruster (United States Agency for International Development); and Leanne Saxon (National Institute for Health and Care Excellence).

The United States Agency for International Development provided financial support for this work. The views of the funding body have not influenced the content of this guideline.

Editing: Green Ink, United Kingdom.

Acronyms and abbreviations

CI	confidence interval
CS	caesarean section
EB	evidence base
GBS	group B Streptococcus
GDG	Guideline Development Group
GRADE	Grading of Recommendations Assessment, Development and Evaluation
GREAT	Guideline development, Research priorities, Evidence synthesis, Applicability of evidence, Transfer of knowledge (a WHO project and international partnership)
hr	hour
HIV	human immunodeficiency virus
IM	intramuscular
IV	intravenous
MCA	[WHO Department of] Maternal, Newborn, Child and Adolescent Health
MD	mean difference
NICU	neonatal intensive care unit
OR	odds ratio
PICO	population, intervention, comparison, outcome
PPROM	preterm prelabour rupture of membranes
PROM	prelabour rupture of membranes
RCT	randomized controlled trial
RHR	[WHO Department of] Reproductive Health and Research
RR	relative risk
UK	United Kingdom
USA	United States of America
WHO	World Health Organization

预览已结束，完整报告链接和二维码

https://www.yunbaogao.cn/report/index/report?report_id=112